ADC Digest - August 2020

ADC Digest - August 2020

Daiichi Sankyo and AstraZeneca entered into a global development and commercialization collaboration for Daiichi Sankyo’s ADC DS-1062

27 Jul 2020

DS-1062 (DNA topoisomerase I inhibitors; Daiichi Sankyo/Astrazeneca)

  • Daiichi Sankyo and AstraZeneca will jointly develop and commercialize DS-1062 worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights
  • Manufacturing and supply of DS-1062 will carried out by Daiichi Sankyo
  • Terms of the agreement:
    • AstraZeneca will pay Daiichi Sankyo an upfront payment of $1 billion: $350 million is due upon execution, $325 million after 12 months and $325 million after 24 months
    • Contingent payments of up to $5 billion: $1 billion for achievement of future regulatory milestones, and $4 billion for sales-related milestones
    • Total payments under the agreement have the potential to reach up to $6 billion
    • Development, commercialization costs and profits from DS-1062 worldwide (except Japan) will be equally shared between both the companies
  • Expected sales region: US, certain countries in EU (Daiichi Sankyo); Other markets worldwide (AstraZeneca)

Daiichi Sankyo and AstraZeneca join hands for development of DS-1062

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share

Our outlook: 

  • For the development of DS-1062, Daiichi Sankyo continues to follow the strategy adopted for ENHERTU. The company has entered into a second global development and commercialization agreement with AstraZeneca for DS-1062 after the initial agreement for ENHERTU in Mar’19
  • ENHERTU was developed and launched in the market earlier than expected using AstraZeneca’s experience and significant expertise in oncology. Daiichi hopes for similar successful regulatory outcomes for DS-1062 as well

– Dr. Kowndinya, CI Scientists

Background:

  • DS-1062, is a TROP2 (trophoblast cell-surface antigen 2) directed DXd antibody drug conjugate (ADC). It is currently in Phase 2 for NSCLC and in Phase 1 for TNBC. Preclinical studies demonstrated DS-1062’s affinity to the TROP2 receptor
  • TROP2 is a transmembrane glycoprotein that is overexpressed in many cancers (up to 80% of TNBC patients)

To read original article click here

Home